ArticleBMJ open2026
Measuring patient adherence in secondary prevention of atherosclerotic cardiovascular disease: a scoping review.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAtherosclerotic cardiovascular disease (ASCVD) is the main cause of death globally, but is by and large a preventable disease. We wished to identify, categorise and map adherence measurements of preventative treatment strategies in patients with ASCVD. DESIGN AND DATA SOURCES: We conducted a scoping review according to the Joanna Briggs Institue (JBI) methodology and Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines. A comprehensive search was performed in PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science and EMBASE (Elsevier Biomedical Research database). The search was conducted in May 2023 and updated in November 2024. ELIGIBILITY CRITERIA: Observational studies pertaining to major types of ASCVD and related preventive treatment with reported adherence measures in adults over the age of 18 were included in this review. DATA EXTRACTION AND SYNTHESIS: Title and abstract and subsequent full-text review were performed by two independent reviewers in duplicate. We presented data from the included 108 studies and synthesised the results in an overview of the most commonly used adherence measurements according to ASCVD category.
resultsA total of 108 records met the inclusion criteria. ASCVD populations included ranged in age from 40 to 91 years, with a male predominance (85%). Medication adherence was mostly reported by the proportion of patients taking their medication (15 studies, 14%) or the proportion of days covered (12 studies, 11%). Among the 108 included studies, 67 (62%) reported on medication adherence, 65 (60%) on smoking cessation, 39 (36%) on low-density lipoprotein cholesterol guideline adherence, 39 (36%) on exercise, 17 (16%) on diet and 11 (10%) on alcohol abstinence. Unspecified patient-reported outcome measures (PROMs) were the most used method for assessing medication adherence, reported in 15 studies (22%).
conclusionMedication adherence was the most frequently assessed domain in secondary prevention of ASCVD, with unspecified PROMs being the most applied measurement approach. Lack of a gold standard combined with inconsistent adherence measures across studies of ASCVD continues to pose a significant challenge for evaluating treatment quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.